Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Corium, StrataGent merge:

This article was originally published in Clinica

  • News

Executive Summary

Transdermal technology specialist Corium International is to merge with StrataGent Life Sciences, a fellow drug delivery company, as part of a $25.1m series C financing. The round was led by Essex Woodlands Health Ventures, which was an investor in StrataGent. The proceeds from the fundraising will be used to develop products based on Corium's MicroCor microneedle and Corplex polymer adhesive technologies, and on StrataGent's liquid microjet drug delivery platform. Robert Thomas, currently CEO of StrataGent and former CEO of FoxHollow Technologies, will serve as CEO of the combined company, while Ron Eastman of Essex Woodlands will become the company's chairman. Corium co-founder Gary Cleary and StrataGent co-founder Ravi Srinivasan will join the board of directors. StrataGent will relocate to Corium's headquarters in Menlo Park, California.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

UK MHRA’s Strategic Approach To AI Will Be ‘Proportionate’ And Fit Well Internationally

Attorney: Proposed Data Privacy Law Would Ultimately Reduce Regulatory Burden

Senseonics Wins Marketing Authorization For Novel Insulin Delivery System

Liquid Biopsy Company Karius Raised $100M To Expand Its Test For Detecting Over 1,000 Pathogens

See All
UsernamePublicRestriction

Register

MT049984

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By